What's New:iOS App Released + New Feb Model Update
S
Superday AI
Sunday ScariesMay 10, 2026

Vol. 3 · Week of May 10, 2026

Sunday Scaries Vol. 3

Powell's chair seat empties May 15 amid the most divided Fed vote since 1992. AI M&A count just jumped 90% YoY. Bullish bought Equiniti for $4.2B. Five-minute recap before Monday.

Welcome back. Powell's final week as Fed chair lands inside the most divided FOMC vote since 1992, AI deal count just jumped 90% year-over-year, and PE on-cycle is reportedly filling about half its usual headcount. Five minutes, every section, ammo for Monday.

Top Stories of the Week

1. Powell's seat empties May 15. The Fed's April vote was the most divided since 1992.

Chair Jerome Powell's term as Fed chair expires May 15. Nominee Kevin Warsh advanced from the Senate Banking Committee on a 13-11 party-line vote but has not been confirmed by the full Senate, so the chair seat is unsettled through the next FOMC meeting. That makes the next six weeks unusually opaque on rates direction. The April 29 hold vote was 8-4, the most FOMC dissents in a single decision since October 1992, and crucially the four dissents split both ways: one governor wanted a cut to support a softening labor market, three regional presidents opposed the statement's easing bias. The committee is split in both directions, not one. Markets that priced in three cuts in January are now pricing in zero for 2026.

Why you care: Rate uncertainty plus a leaderless Fed is the single largest overhang on sponsor-coverage deal flow heading into summer. Pipelines your target groups are working on get repriced every time spread expectations move.

Interview angle: "The 8-4 split says the Fed's next move is genuinely uncertain. With Powell out May 15 and no successor named, expect spread volatility through the summer. Sponsor coverage groups are baking wider rate-bands into LBO models right now."

2. Trump and Xi meet May 14-15. Iran is eating the trade agenda.

President Trump and Xi Jinping meet in Beijing on May 14 and 15. Per CNBC reporting on May 8, Iran has become the dominant agenda item, likely crowding out progress on tariffs and rare earths. U.S. tariffs on Chinese goods sit around 30% headline (down from last year's 145% peak), though the Supreme Court's recent IEEPA ruling has thrown some of the layering into flux. Treasury Secretary Bessent has said Iran will be central. Boeing CEO Kelly Ortberg and Citigroup CEO Jane Fraser are reportedly traveling with Trump, putting industrial diplomacy and capital markets on the table. A summit that produces nothing on trade extends the wait-and-see posture among strategic acquirers.

Why you care: Tariff overhang is the largest single drag on cross-border M&A in 2026. Industrial, defense, and tech acquirers are not moving until they have a clear read on the next tariff step.

Interview angle: "Asia-Pacific cross-border deal count is still trailing 2023 levels because tariff uncertainty is keeping strategic acquirers on hold. Watch the May 14-15 summit. If Iran crowds out trade, advisors will be building more tariff-contingency analysis into diligence into Q3."

3. AI deal count jumped 90% in Q1. Roche bought PathAI. IonQ closed SkyWater.

Q1 2026 logged 266 AI-related transactions, up 90% from 140 in Q1 2025, per Intrepid IB's May M&A monthly. Two AI-linked deals cleared milestones this past week. Roche announced a $1.05B acquisition of PathAI on May 7 (digital pathology). IonQ's $1.8B deal for SkyWater Technology cleared shareholder approval on May 8, creating the only vertically integrated quantum-computing platform in public markets. Same playbook in both: buy the infrastructure layer before it gets priced into a platform multiple.

Why you care: AI is the dominant deal thesis across healthcare, TMT, FIG, and industrials. Bankers are spending as much time on AI moat analysis as on traditional DCF, and your interviewers will expect a view.

Interview angle: "Roche/PathAI is biopharma using tuck-in AI buys to defend a diagnostics moat instead of building internally. The same pattern shows up across healthcare and life sciences deal flow this year. If you're targeting healthcare or TMT, that's the lens."

Deals of the Week

Bullish acquires Equiniti from Siris Capital, $4.2B. Announced May 5. About $1.85B in assumed debt plus roughly $2.35B in Bullish stock at the $38.48 VWAP. A crypto-native exchange buying a traditional transfer agent that serves 20 million shareholders. Thesis: tokenized securities. PE exit for Siris Capital, pro forma combined ~$500M+ adjusted EBITDA less capex on ~$1.3B revenue.

  • Bullish advisors: Goldman Sachs (financial); Morgan, Lewis & Bockius (legal)
  • Equiniti / Siris advisors: Evercore, FT Partners (financial); Sidley Austin (legal)

Bayer acquires Perfuse Therapeutics, up to $2.45B. Announced May 6. $300M upfront plus up to $2.15B in milestones. Bayer's first major acquisition in years, ending the Monsanto-driven deleveraging drought. Lead asset PER-001 is a Phase II intravitreal therapy targeting glaucoma and diabetic retinopathy as Eylea faces biosimilar erosion.

  • Bayer advisors: BofA Securities (financial); Baker McKenzie (legal)
  • Perfuse advisors: Centerview Partners (financial); Goodwin Procter (legal)

IonQ's $1.8B SkyWater deal cleared shareholder approval on May 8. Originally announced January 2026, $15 cash plus $20 IonQ stock per SkyWater share. Vote: 32.6M for, 0.4M against. Creates the only vertically integrated quantum company in public markets. Defense, pharma, and finance are the target end markets.

  • IonQ advisors: Cantor Fitzgerald, BofA Securities (financial); Paul, Weiss (legal)
  • SkyWater advisors: Goldman Sachs (financial); Foley & Lardner (legal)

Pro tip: Pick one. Know it cold by Friday. Bullish/Equiniti (tokenization) and Bayer/Perfuse (pharma pipeline rebuild) are the two with the cleanest interview hooks this week.

Recruiting Pulse

PE on-cycle is filling about half its usual headcount. Candidates we talk to are reporting that headhunters at major shops are filling roughly 50% of typical on-cycle slots. Names floating in those conversations include Vista, Silver Lake, Blackstone, and Apollo. Deal-flow recovery is real, but firms are not rebuilding teams at the same pace. AI-assisted diligence is absorbing volume that previously required larger associate classes. If you have a strong return offer, take time to prepare rather than rushing into off-cycle.

BofA, Citi, and Wells projected lower 2026 IB analyst headcounts. Banking Dive reported this week that all three are running lean by design. BofA quietly cut 100+ analysts and associates earlier this year through performance reviews. The posture across the bulge is to manage through attrition, with AI tools absorbing routine analytical work. The two-year exit window is compressing, but actual firing rates remain modest relative to 2023's wave.

AI sector fluency is now a superday expectation, not an edge. Recent grads we work with say bulge-bracket interviewers are routinely asking how AI changes the deal-making in your target sector, most consistently in healthcare, TMT, and FIG. One Goldman healthcare superday question we heard this past month: how would AI change how a hospital system thinks about M&A? Have a one-minute answer ready for any sector group, before the interview.

What's New on Superday AI

Three things worth your time this week:

We just crossed 1,000 active users.

Thanks for the trust. A wave of upgrades to mocks, drills, and firm-specific question banks ships across the next few weeks. If you're not on the platform yet, the trial covers every feature.

Start your free trial
AI-Powered Interview Prep

Want this in your inbox every Sunday?

Free. Five minutes. Built for college students who want the IB news that actually moves recruiting forward.

More Sunday Scaries

Ready to ace your interview?

The #1 AI prep tool for investment banking interviews

Built by Wall Street insiders and used on 50+ campuses. Practice until you're ready — not until you run out of flashcards.

Try Free Today

1,500+ Drills

Technical questions with instant feedback

Mock Interviews

AI-powered realistic interview practice

AI Coaching

Personalized prep plans for your target banks

Resume Analyzer

Score your candidacy against real data